Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Feb. 11, 2014

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Feb. 11, 2014

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

Feb. 11, 2014

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Feb. 11, 2014

arGEN-X begins phase Ib study of ARGX-111

Feb. 11, 2014

Kyowa Hakko Kirin alters supplemental application for Poteligio in Japan

Feb. 10, 2014

Phase II results show prolonged immune responses with DN24-02 in patients with urothelial cancer

Feb. 10, 2014

TG-01 enters phase IIa trial in operable pancreatic cancer

Feb. 7, 2014

Preliminary phase I results show safety of DC-Ad-GMCAIX treatment in patients with RCC

Feb. 6, 2014

PSMA-ADC treatment leads to CTC and PSA reductions in patients with metastatic CRPC

Feb. 6, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...